Nanobiotix Aktie
2,88EUR | -0,10EUR | -3,42% |
WKN DE: A1J7EB / ISIN: FR0011341205
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 90 | 100 | 102 | 102 | 108 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,29 | -0,11 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 125 | 93 | 52 | 87 | 61 |
Summe Anlagevermögen | 9 | 9 | 7 | 7 | 6 |
Summe Aktiva | 134 | 102 | 60 | 94 | 67 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 64 | 75 | 87 | 96 | 133 |
Summe Eigenkapital | 70 | 27 | -27 | -2 | -66 |
Summe Passiva | 134 | 102 | 60 | 94 | 67 |
Adresse
60, rue de Wattignies, 75012 Paris | |
Telefon | +33 (1) 40-26-04-70 |
Fax | +33 (1) 40-26-04-44 |
Internet | http://www.nanobiotix.com |
Management
Alain Herrera
Member-Supervisory Board |
Anne-Juliette Hermant
Chief People Officer |
Anne-Marie Graffin
Deputy Chairman-Supervisory Board |
Bart van Rhijn
Chief Financial & Business Officer |
Craig West
Senior Vice President-Investor Relations |
Enno Spillner
Member-Supervisory Board |
Gary M. Phillips
Chairman-Supervisory Board |
Laurent Lévy
Chairman-Executive Board & Chief Executive Officer |
Louis Kayitalire
Chief Medical Officer |
Margaret Galluzzi
Vice President & Head-Global Clinical Operations |
Patrick Tricoli
Global Head-Business Development |